## Amendments to the Specification

Please amend the paragraph that begins on page 23, line 17 as follows:

-- The invention further encompasses methods of using and pharmaceutical compositions comprising a racemic or optically pure sibutramine metabolite, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, in combination with a phosphodiesterase inhibitor. Examples of phosphodiesterase inhibitors that can be used in compositions and methods of the invention include, but are not limited to, those disclosed in U.S. Patent No. 5,250,534; U.S. Patent No. 5,719,283; U.S. Patent No. 6,127,363; WO 94/28902; WO 97/03675; WO 98/06722, all of which are expressly incorporated herein by reference in their entirety. Preferred phosphodiesterase inhibitors are PDE5 and PDE6 inhibitors. Particular phosphodiesterase inhibitors include, but are not limited to, sildenophil sildenafil (Viagra®), desmethylsildenophil desmethylsildenafil, vinopocetine vinpocetine, milrinone, amrinone, pimobendan, cilostamide, enoximone, peroximone, vesnarinone, rolipran, R020-1724, zaprinast, dipyridamole, and pharmaceutically acceptable salts, solvates, hydrates, clathrates, prodrugs, optically and pharmacologically active stereoisomers, and pharmacologically active metabolites thereof.--

Please amend the paragraph that begins on page 24, line 3 as follows:

-- While all combinations of racemic and optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrate thereof, and one or more of the above-described pharmacologically active compounds can be useful and valuable, certain combinations are particularly preferred. Examples of preferred combinations include those wherein a racemic or optically pure sibutramine metabolite, or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, is combined with one of the following:

tertatolol; alprazolam; mesoridazine; desipramine; brotizolam; thioridazine; clonidine; chlordiazepoxide; acetophenazine; olanzapine; clobazam; fluphenazine; methylphenidate; perphenazine; clonazepam; buspirone; clorazepate; trifluoperazine; hydroxyzine; chlorprothixene; demoxepam; thiothixene; tomoxetine; diazepam; sildenophil sildenafil; estazolam; clozapine; desmethylsildenophil desmethylsildenafil; flumazenil; haloperidol;

CAJD-535825v1 3

flurazepam;	loxapine;	vinopocetine vinpocetine;
halazepam;	molindone;	milrinone;
lorazepam;	pimozide;	amrinone;
midazolam;	risperidone;	pimobendan;
nitrazepam;	alprenolol;	cilostamide;
nordazepam;	WAY 100135;	enoximone;
oxazepam;	spiperone;	peroximone;
prazepam;	S(S)-pindolol;	vesnarinone;
quazepam;	R(R)-pindolol;	rolipran;
temazepam;	racemic pindolol;	R020-1724;
triazolam;	(S)-UH-301;	zaprinast; or
chlorpromazine:	penbutolol;	dipyridamole

CAJD-535825v1